Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company
Business live – latest updates
The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and profits as health systems around the world rush to use it to tackle obesity.
Sales of the Danish pharmaceutical company Novo Nordisk’s diabetes and obesity drugs rose from 113bn Danish kroner (£13.2bn) in the nine months to the end of September 2022 to 154bn kroner for the same period in 2023.
About Author
More Stories
Nvidia’s CEO makes surprise visit to Beijing after US restricts chip sales to China
Nvidia expects to take $5.5bn hit as US tightens AI chip export rules to China
Move over, Med diet – plantains and cassava can be as healthy as tomatoes and olive oil, say researchers